Current clinical strategies for evaluating prognosis in PCa at the time of diagnosis include the determination of anatomical extent, histologic grade (Gleason score) and serum levels of prostate-specific antigen (PSA). This evidence concerns the gene KLK3 and posterior cortical atrophy.